Literature DB >> 23732524

Differentiation therapy for IDH1/2 mutant malignancies.

Francine E Garrett-Bakelman1, Ari M Melnick.   

Abstract

Recently discovered recurrent somatic mutations in the key metabolic enzymes IDH1 and IDH2 produce the aberrant oncometabolite 2-HG and contribute to malignant transformation of hematopoietic and glial cells. Two recent reports in Science describe the first IDH1 and IDH2 mutant-specific small-molecule inhibitors, which induce cell differentiation of myeloid leukemias and malignant gliomas.

Entities:  

Year:  2013        PMID： 23732524      PMCID： PMC3731561          DOI： 10.1038/cr.2013.73

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


  10 in total

1.  IDH mutation impairs histone demethylation and results in a block to cell differentiation.

Authors:  Chao Lu; Patrick S Ward; Gurpreet S Kapoor; Dan Rohle; Sevin Turcan; Omar Abdel-Wahab; Christopher R Edwards; Raya Khanin; Maria E Figueroa; Ari Melnick; Kathryn E Wellen; Donald M O'Rourke; Shelley L Berger; Timothy A Chan; Ross L Levine; Ingo K Mellinghoff; Craig B Thompson
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

Review 2.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

3.  IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.

Authors:  Masato Sasaki; Christiane B Knobbe; Joshua C Munger; Evan F Lind; Dirk Brenner; Anne Brüstle; Isaac S Harris; Roxanne Holmes; Andrew Wakeham; Jillian Haight; Annick You-Ten; Wanda Y Li; Stefanie Schalm; Shinsan M Su; Carl Virtanen; Guido Reifenberger; Pamela S Ohashi; Dwayne L Barber; Maria E Figueroa; Ari Melnick; Juan-Carlos Zúñiga-Pflücker; Tak W Mak
Journal:  Nature       Date:  2012-08-30       Impact factor: 49.962

Review 4.  IDH mutations in glioma and acute myeloid leukemia.

Authors:  Lenny Dang; Shengfang Jin; Shinsan M Su
Journal:  Trends Mol Med       Date:  2010-08-05       Impact factor: 11.951

Review 5.  Acute promyelocytic leukemia: from highly fatal to highly curable.

Authors:  Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2008-03-01       Impact factor: 22.113

6.  D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.

Authors:  Masato Sasaki; Christiane B Knobbe; Momoe Itsumi; Andrew J Elia; Isaac S Harris; Iok In Christine Chio; Rob A Cairns; Susan McCracken; Andrew Wakeham; Jillian Haight; Annick You Ten; Bryan Snow; Takeshi Ueda; Satoshi Inoue; Kazuo Yamamoto; Myunggon Ko; Anjana Rao; Katharine E Yen; Shinsan M Su; Tak Wah Mak
Journal:  Genes Dev       Date:  2012-08-27       Impact factor: 11.361

7.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

8.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

9.  (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.

Authors:  Julie-Aurore Losman; Ryan E Looper; Peppi Koivunen; Sungwoo Lee; Rebekka K Schneider; Christine McMahon; Glenn S Cowley; David E Root; Benjamin L Ebert; William G Kaelin
Journal:  Science       Date:  2013-02-07       Impact factor: 47.728

10.  Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.

Authors:  Fang Wang; Jeremy Travins; Byron DeLaBarre; Virginie Penard-Lacronique; Stefanie Schalm; Erica Hansen; Kimberly Straley; Andrew Kernytsky; Wei Liu; Camelia Gliser; Hua Yang; Stefan Gross; Erin Artin; Veronique Saada; Elena Mylonas; Cyril Quivoron; Janeta Popovici-Muller; Jeffrey O Saunders; Francesco G Salituro; Shunqi Yan; Stuart Murray; Wentao Wei; Yi Gao; Lenny Dang; Marion Dorsch; Sam Agresta; David P Schenkein; Scott A Biller; Shinsan M Su; Stephane de Botton; Katharine E Yen
Journal:  Science       Date:  2013-04-04       Impact factor: 63.714
  10 in total
  8 in total

1.  Inhibitors of Mutant IDH for the Treatment of Cancer.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2014-10-07       Impact factor: 4.345

Review 2.  Retinoic acid signaling and neuronal differentiation.

Authors:  Amanda Janesick; Stephanie Cherie Wu; Bruce Blumberg
Journal:  Cell Mol Life Sci       Date:  2015-01-06       Impact factor: 9.261

3.  Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors.

Authors:  Tahir N Sheikh; Xiao Chen; Xinjing Xu; John T McGuire; Matthew Ingham; Chao Lu; Gary K Schwartz
Journal:  Mol Cancer Ther       Date:  2021-09-22       Impact factor: 6.009

4.  Different Effects of RNAi-Mediated Downregulation or Chemical Inhibition of NAMPT in an Isogenic IDH Mutant and Wild-Type Glioma Cell Model.

Authors:  Maximilian Clausing; Doreen William; Matthias Preussler; Julia Biedermann; Konrad Grützmann; Susan Richter; Frank Buchholz; Achim Temme; Evelin Schröck; Barbara Klink
Journal:  Int J Mol Sci       Date:  2022-05-21       Impact factor: 6.208

5.  SAR insights into TET2 catalytic domain inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates.

Authors:  Anand D Tiwari; Yihong Guan; Dale R Grabowski; Jaroslaw P Maciejewski; Babal K Jha; James G Phillips
Journal:  Bioorg Med Chem       Date:  2021-04-20       Impact factor: 3.461

6.  Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.

Authors:  Elisabet Cuyàs; Salvador Fernández-Arroyo; Bruna Corominas-Faja; Esther Rodríguez-Gallego; Joaquim Bosch-Barrera; Begoña Martin-Castillo; Rafael De Llorens; Jorge Joven; Javier A Menendez
Journal:  Oncotarget       Date:  2015-05-20

7.  Identification of glioblastoma gene prognosis modules based on weighted gene co-expression network analysis.

Authors:  Pengfei Xu; Jian Yang; Junhui Liu; Xue Yang; Jianming Liao; Fanen Yuan; Yang Xu; Baohui Liu; Qianxue Chen
Journal:  BMC Med Genomics       Date:  2018-11-01       Impact factor: 3.063

8.  Integrated Analysis to Evaluate the Prognostic Value of Signature mRNAs in Glioblastoma Multiforme.

Authors:  Ji'an Yang; Long Wang; Zhou Xu; Liquan Wu; Baohui Liu; Junmin Wang; Daofeng Tian; Xiaoxing Xiong; Qianxue Chen
Journal:  Front Genet       Date:  2020-03-31       Impact factor: 4.599
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.